Meta and EssilorLuxottica Sued for Patent Infringement on Ray-Ban Meta
Solos Technology, an American company specializing in smart glasses, has filed a lawsuit in the Federal District Court of Massachusetts against Meta Platforms and EssilorLuxottica. The company accuses the two groups of infringing on several of its patents related to technologies used in Ray-Ban Meta glasses.
Solos Technology challenges the use of technologies covered by its patents in the Ray-Ban Meta glasses marketed by EssilorLuxottica in partnership with Meta. The lawsuit specifically addresses innovations including multimodal detection, sensor fusion, audio processing, context and activity determination, as well as integrated system architectures enabling real-time interaction. According to Solos, these technologies are central to the functionalities of the glasses in question.
Claims for Billions in Damages and Injunctive Relief
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Solos is seeking several billion dollars in damages and is requesting an injunction to prevent further patent infringements. The press release does not specify the exact amount demanded or the timeline of the judicial proceedings.
No Public Comment from Meta or EssilorLuxottica
As of the date of the press release, neither Meta nor EssilorLuxottica have publicly commented on the lawsuit. No information regarding their defense strategy has been disclosed.
C’est une année historique pour EssilorLuxottica : pour la première fois depuis l’origine du Groupe, notre chiffre d’affaires a enregistré une croissance à deux chiffres à taux de change constant, après un quatrième trimestre affichant une croissance record de 18,4 %.
Résultats annuels 2025 marquent une croissance du chiffre d’affaires de 11,2% et une marge opérationnelle ajustée de 15,7%; le cash-flow libre atteint 2,8 milliards d'euros; dividende proposé de 4,00 euros; acquisitions et initiatives med-tech renforcent le positionnement.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
